<DOC>
	<DOCNO>NCT01676441</DOCNO>
	<brief_summary>This phase II/III clinical trial design evaluate safety efficacy autologous Mesenchymal Stem Cells ( MSC ) transplant directly injure spinal cord .</brief_summary>
	<brief_title>Safety Efficacy Autologous Mesenchymal Stem Cells Chronic Spinal Cord Injury</brief_title>
	<detailed_description>The Principal investigator perform clinical trial use autologous MSCs patient cervical spinal cord injury . The result reveal safety autologous MSC . This Phase II , III single-center trial ass safety efficacy bone marrow-derived mesenchymal stem cell transplantation direct injured spinal cord site via laminectomy . After recovery operation , subject receive 4 week physical occupational therapy .</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<criteria>Aged 1665 year Traumatic spinal cord injury level cervical American Spinal Injury Association Impairment Scale B 12 month post spinal cord injury subject stable neurological find 1 month rehabilitation therapy No sign contracture Good physical condition go operation Must willing able participate study procedure mental verbal problem Able consent patient legal representative Serum SGOT/SGPT &gt; 3 X upper limit normal Creatinine &gt; 1.5 X upper limit normal Major surgical procedure past 3 month Penetrating injury Mechanical ventilation Serious preexist medical condition Recently diagnose infection ( Urinary tract infection , Pneumonia etc ) Positive skin test penicillin Positive result viral marker ( human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) Venereal Disease Research Laboratory ( VDRL ) test ) Pregnant woman , woman childbearing potential want adequate contraception , breastfeed female Unwilling participate study Patients psychiatric disorder severe make compliance treatment unlike , sign inform consent impossible Drug abuse past 1 year Participating clinical trial past 1 month Inappropriate patient participate study accord chief investigator</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>spinal cord injury</keyword>
	<keyword>mesenchymal stem cell</keyword>
</DOC>